- Crohn's disease (CD) and ulcerative colitis (UC) evolve with alternate outbreaks and remissions of variable duration in both cases. Tumor necrosis factor α antagonists (anti-TNF) have advanced in the treatment of patients with inflammatory bowel disease (IBD), which has improved the patient's quality of life by reducing the number of surgeries and hospitalizations.
- Despite these advances, about 30% of patients do not respond to initial treatment after the induction period, and 20% to 50% of patients should be optimized to respond to treatment.
- The prognosis of the outcome of the treatment is of great value in shaping the therapeutic strategy for these patients.
- The use of RAID-Response will allow to significantly increase the efficacy of the therapies per patients of Crohn’s disease and ulcerative colitis, increase their quality of life and reduce important associated costs.
- A clinical study is currently being carried out together with Hospital Universitari Dr Josep Trueta, Hospital Bellvitge, Institut d'Assistència Sanitària and Hospital Germans Trias i Pujol. We expect to launch it on the market by 2021.
- RAID-Response will be on the market for patients who have been diagnosed with Crohn’s disease or ulcerative colitis.
INVIERTE GoodGut celebra su quinto aniversario con varios hitos empresariales, médicos y científicos ...
GoodGut has signed an agreement with Palex Medical to start selling its new ...
The International Society for Gastrointestinal Hereditary Tumours (InSiGHT) and the New Zealand Society ...